{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:32:19Z","timestamp":1794468739707,"version":"4.9.1"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.biomaterials.2026.124551","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:36:59Z","timestamp":1786981019000},"page":"124551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Logic-gated nanoregulators: A paradigm shift from drug delivery to pre-programmed multi-target immunotherapy"],"prefix":"10.1016","volume":"337","author":[{"given":"Yimao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Zengin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7054-448X","authenticated-orcid":false,"given":"Meng-Yao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7637","key":"10.1016\/j.biomaterials.2026.124551_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124551_bib3","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"6230","key":"10.1016\/j.biomaterials.2026.124551_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"Cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124551_bib5","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","article-title":"The tumor microenvironment innately modulates cancer progression","volume":"79","author":"Hinshaw","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124551_bib7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124551_bib11","article-title":"Overcoming cancer therapy resistance: from drug innovation to therapeutics","volume":"81","author":"Wei","year":"2025","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"issue":"34","key":"10.1016\/j.biomaterials.2026.124551_bib12","doi-asserted-by":"crossref","first-page":"30720","DOI":"10.1021\/acsnano.5c02321","article-title":"Advances in nanomedicine for targeting cancer stem cells and overcoming therapeutic resistance","volume":"19","author":"Zhang","year":"2025","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124551_bib13","doi-asserted-by":"crossref","first-page":"5440","DOI":"10.7150\/thno.112475","article-title":"Nano drug delivery systems for advanced immune checkpoint blockade therapy","volume":"15","author":"Guo","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.biomaterials.2026.124551_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114155","article-title":"Macrophage hitchhiking for smart nanomedicine: bridging immune navigation and targeted therapy","volume":"386","author":"Zhang","year":"2025","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124551_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.curpro.2025.100055","article-title":"Spatial omics: deciphering heterogeneity in the tumor immune microenvironment and resistance to immunotherapy","volume":"22","author":"Li","year":"2025","journal-title":"Curr. Proteom."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41571-025-01000-6","article-title":"Enhancing immunotherapy with tumour-responsive nanomaterials","volume":"22","author":"Linderman","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-022-00699-x","article-title":"Targeting drugs to tumours using cell membrane-coated nanoparticles","volume":"20","author":"Fang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib18","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12943-025-02443-2","article-title":"Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics","volume":"24","author":"Yang","year":"2025","journal-title":"Mol. Cancer"},{"issue":"21","key":"10.1016\/j.biomaterials.2026.124551_bib19","doi-asserted-by":"crossref","first-page":"9807","DOI":"10.1039\/D5CS00608B","article-title":"Photoactivated nanovaccines","volume":"54","author":"Ding","year":"2025","journal-title":"Chem. Soc. Rev."},{"issue":"50","key":"10.1016\/j.biomaterials.2026.124551_bib20","article-title":"Omics-enhanced nanomedicine for cancer therapy","volume":"36","author":"Qi","year":"2024","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib21","article-title":"Bioinspired and biomimetic delivery platforms for cancer vaccines","volume":"34","author":"Liu","year":"2022","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41568-020-00329-7","article-title":"The matrix in cancer","volume":"21","author":"Cox","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12967-025-06306-8","article-title":"Mechanical forces in the tumor microenvironment: roles, pathways, and therapeutic approaches","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib24","first-page":"348","article-title":"Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer","volume":"5","author":"Li","year":"2024","journal-title":"Med N. Y. N"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib25","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/s41467-021-24009-8","article-title":"Co-Evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance","volume":"12","author":"Pietil\u00e4","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biomaterials.2026.124551_bib26","article-title":"Exploiting mechanoregulation via FAK\/YAP to overcome platinum resistance in ovarian cancer","volume":"179","author":"Dang","year":"2024","journal-title":"Biomed. Pharmacother. Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124551_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202502356","article-title":"Hui-Xiang decoction against pancreatic cancer by regulating AKT and activating the hippo signaling pathway","volume":"23","author":"Zhang","year":"2026","journal-title":"Chem. Biodivers."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124551_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s11433-019-1528-y","article-title":"Excellent thermoelectric performance in weak-coupling molecular junctions with electrode doping and electrochemical gating","volume":"63","author":"Wu","year":"2020","journal-title":"Sci. China Phys. Mech. Astron."},{"key":"10.1016\/j.biomaterials.2026.124551_bib29","first-page":"57","article-title":"Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer","volume":"8","author":"Xu","year":"2025","journal-title":"Cancer Drug Resist."},{"issue":"20","key":"10.1016\/j.biomaterials.2026.124551_bib30","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/s41388-025-03317-z","article-title":"ITGB1\/FERMT1 mechanoactivation enhances CD44 characteristic stemness in oral squamous cell carcinoma via ubiquitin-dependent CK1\u03b1 degradation","volume":"44","author":"Li","year":"2025","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.devcel.2019.03.026","article-title":"The extracellular matrix modulates the metastatic journey","volume":"49","author":"Kai","year":"2019","journal-title":"Dev. Cell"},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124551_bib32","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1021\/acsnano.8b07865","article-title":"Dexamethasone increases cisplatin-loaded nanocarrier delivery and efficacy in metastatic breast cancer by normalizing the tumor microenvironment","volume":"13","author":"Martin","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124551_bib33","article-title":"Breaking down physical barriers: strategies to improve lymphocyte infiltration for effective neoantigen-based therapies","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib34","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13402-021-00602-3","article-title":"Angiogenesis as a hallmark of solid tumors - clinical perspectives","volume":"44","author":"Majidpoor","year":"2021","journal-title":"Cell. Oncol. Dordr. Neth."},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124551_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130748","article-title":"Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells","volume":"4","author":"Peereboom","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.biomaterials.2026.124551_bib36","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.3389\/fimmu.2019.02936","article-title":"Immune checkpoints in circulating and tumor-infiltrating CD4+ T cell subsets in colorectal cancer patients","volume":"10","author":"Toor","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biomaterials.2026.124551_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2020.01.002","article-title":"Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-Grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer","volume":"128","author":"Liu","year":"1990","journal-title":"Eur. J. Cancer Oxf. Engl."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124551_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/INMD.20250016","article-title":"Patient-derived xenograft models in pan-cancer: from bench to clinic","volume":"3","author":"Li","year":"2025","journal-title":"Interdiscip. Med."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib39","article-title":"Phase 2 trial of perioperative chemo-immunotherapy for gastro-esophageal adenocarcinoma: the role of M2 macrophage landscape in predicting response","volume":"6","author":"Alcindor","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124551_bib40","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-20-3416","article-title":"Regorafenib-Avelumab combination in patients with microsatellite stable colorectal cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"27","author":"Cousin","year":"2021","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124551_bib41","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00262-020-02758-7","article-title":"Inflammatory cell-associated tumors. Not only macrophages (TAMs), fibroblasts (TAFs) and neutrophils (TANs) can infiltrate the tumor microenvironment. The unique role of tumor associated platelets (TAPs)","volume":"70","author":"Dymicka-Piekarska","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ptr.6784","article-title":"A survey of herbal medicines as tumor microenvironment-modulating agents","volume":"35","author":"Park","year":"2021","journal-title":"Phytother. Res. PTR"},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15669","article-title":"Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-Expressing small adipocytes","volume":"184","author":"Mehdi","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003892","article-title":"Direct targeting of FOXP3 in tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer","volume":"10","author":"Revenko","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124551_bib45","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","article-title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages","volume":"30","author":"Gomez-Roca","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124551_bib47","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/neuonc\/noae105","article-title":"Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy","volume":"26","author":"Noh","year":"2024","journal-title":"Neuro Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmed.2026.100032","article-title":"New insights into microbiome metabolic mechanisms for pancreatic cancer therapy","volume":"1","author":"Wu","year":"2026","journal-title":"TransMed"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib49","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/gutjnl-2024-333617","article-title":"CAF-macrophage crosstalk in tumour microenvironments governs the response to immune checkpoint blockade in gastric cancer peritoneal metastases","volume":"74","author":"Li","year":"2025","journal-title":"Gut"},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124551_bib50","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-19-1090","article-title":"A phase I study of the Anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors","volume":"25","author":"Doi","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124551_bib51","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-20-0113","article-title":"Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial","volume":"26","author":"Wang","year":"2020","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/med4.70044","article-title":"Neuronal reshaping of the tumor microenvironment in tumorigenesis and metastasis: Bench to clinic","volume":"3","author":"Wu","year":"2025","journal-title":"Med. Adv."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124551_bib53","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1021\/acs.molpharmaceut.1c00455","article-title":"Tumor-associated fibroblast-targeting nanoparticles for enhancing solid tumor therapy: progress and challenges","volume":"18","author":"Li","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biomaterials.2026.124551_bib54","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2019.01.032","article-title":"Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy","volume":"448","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124551_bib55","article-title":"Unlocking the potential: targeting metabolic pathways in the tumor microenvironment for cancer therapy","volume":"1879","author":"Jia","year":"2024","journal-title":"Biochim. Biophys. Acta BBA - Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib56","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12943-024-02221-6","article-title":"Unveiling the immunomodulatory dance: endothelial cells' function and their role in non-small cell lung cancer","volume":"24","author":"Daum","year":"2025","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124551_bib57","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1158\/0008-5472.CAN-24-4744","article-title":"Transforming cancer therapy: unlocking the potential of targeting vascular and stromal cells in the tumor microenvironment","volume":"85","author":"Liu","year":"2025","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41392-024-02105-7","article-title":"Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma","volume":"10","author":"Zheng","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124551_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007854","article-title":"Epithelium\/imcDC2 axis facilitates the resistance of neoadjuvant Anti-PD-1 in human NSCLC","volume":"12","author":"Chen","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"14","key":"10.1016\/j.biomaterials.2026.124551_bib60","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-23-2808","article-title":"Phase I study of GS-3583, an FMS-Like tyrosine kinase 3 agonist Fc fusion protein, in patients with advanced solid tumors","volume":"30","author":"Tolcher","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s40242-020-9103-8","article-title":"Stabilizing high-voltage cathode materials for next-generation Li-Ion batteries","volume":"36","author":"Zhu","year":"2020","journal-title":"Chem. Res. Chin. Univ."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib62","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005301","article-title":"First-in-Human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"8048","key":"10.1016\/j.biomaterials.2026.124551_bib63","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome Anti-PD-1 and Anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.biomaterials.2026.124551_bib64","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1158\/0008-5472.CAN-24-4383","article-title":"Tumor-specific MHC-II activates CD4+ and CD8+ T cells in head and neck squamous cell carcinoma to boost immunotherapy efficacy","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124551_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005424","article-title":"Phase I\/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-na\u00efve and PD-1 antibody-experienced patients with melanoma (MEL64)","volume":"10","author":"Vavolizza","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001621","article-title":"Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma","volume":"9","author":"Malvehy","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib67","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007340","article-title":"Phase 1\/2 study of monalizumab plus durvalumab in patients with advanced solid tumors","volume":"12","author":"Patel","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124551_bib68","article-title":"Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study","volume":"12","author":"T","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib69","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s41392-021-00745-7","article-title":"Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib70","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12916-026-04870-4","article-title":"The neuroimmune axis in breast cancer: from mechanistic insights to clinical applications","volume":"24","author":"Wu","year":"2026","journal-title":"BMC Med."},{"issue":"20","key":"10.1016\/j.biomaterials.2026.124551_bib71","doi-asserted-by":"crossref","first-page":"11252","DOI":"10.1002\/anie.202101938","article-title":"Improving bioavailability of hydrophobic prodrugs through supramolecular nanocarriers based on recombinant proteins for osteosarcoma treatment","volume":"60","author":"Wang","year":"2021","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.biomaterials.2026.124551_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2024.103318","article-title":"Loading bioactive peptides within different nanocarriers to enhance their functionality and bioavailability; in vitro and in vivo studies","volume":"334","author":"Mazloomi","year":"2024","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.biomaterials.2026.124551_bib73","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jcis.2022.12.162","article-title":"Self-assembling nanoarchitectonics of size-controllable celastrol nanoparticles for efficient cancer chemotherapy with reduced systemic toxicity","volume":"636","author":"Liu","year":"2023","journal-title":"J. Colloid Interface Sci."},{"issue":"47","key":"10.1016\/j.biomaterials.2026.124551_bib74","doi-asserted-by":"crossref","first-page":"55902","DOI":"10.1021\/acsami.1c17618","article-title":"Stable loading and delivery of melittin with lipid-coated polymeric nanoparticles for effective tumor therapy with negligible systemic toxicity","volume":"13","author":"Ye","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib75","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70059","article-title":"Patient-derived xenograft model in cancer: establishment and applications","volume":"6","author":"Gu","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.biomaterials.2026.124551_bib76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2022.05.017","article-title":"Halofuginone micelle nanoparticles eradicate Nrf2-Activated lung adenocarcinoma without systemic toxicity","volume":"187","author":"Panda","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.biomaterials.2026.124551_bib77","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jconrel.2024.02.007","article-title":"Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma","volume":"367","author":"Logan","year":"2024","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124551_bib78","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.7150\/thno.39560","article-title":"Probing and enhancing ligand-mediated active targeting of tumors using Sub-5 Nm ultrafine iron oxide nanoparticles","volume":"10","author":"Xu","year":"2020","journal-title":"Theranostics"},{"issue":"50","key":"10.1016\/j.biomaterials.2026.124551_bib79","doi-asserted-by":"crossref","first-page":"27838","DOI":"10.1021\/jacs.3c11328","article-title":"Smart lipid nanoparticle that remodels tumor microenvironment for activatable H2S gas and photodynamic immunotherapy","volume":"145","author":"Wu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib80","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1021\/acsnano.3c10037","article-title":"Tumor-microenvironment-activatable nanoparticle mediating immunogene therapy and M2 macrophage-targeted inhibitor for synergistic cancer immunotherapy","volume":"18","author":"Hu","year":"2024","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib81","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12951-022-01241-y","article-title":"Cocktail strategy based on a dual function nanoparticle and immune activator for effective tumor suppressive","volume":"20","author":"Li","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124551_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.123043","article-title":"Targeting \u03b2-Catenin using XAV939 nanoparticle promotes immunogenic cell death and suppresses conjunctival melanoma progression","volume":"640","author":"Antony","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib83","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1021\/acsnano.4c00654","article-title":"Tumor vaccine exploiting membranes with influenza virus-induced immunogenic cell death to decorate polylactic coglycolic acid nanoparticles","volume":"19","author":"Yang","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2026.124551_bib85","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jconrel.2024.10.042","article-title":"Immunomodulatory microneedle patch for enhanced ferroptosis and immunogenic cell death in postoperative tumor therapy","volume":"376","author":"Wang","year":"2024","journal-title":"J. Contr. Release"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib86","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/acsami.2c17579","article-title":"Carrier-free nanoplatform via evoking pyroptosis and immune response against breast cancer","volume":"15","author":"Li","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biomaterials.2026.124551_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2025.114740","article-title":"Multifunctional Cascade theranostic agents for synergistic photothermal\/ferroptosis\/immuno antitumor therapy","volume":"253","author":"Chen","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib87","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1039\/D0NR05832G","article-title":"Nanocarrier-based activation of necroptotic cell death potentiates cancer immunotherapy","volume":"13","author":"Xia","year":"2021","journal-title":"Nanoscale"},{"issue":"23","key":"10.1016\/j.biomaterials.2026.124551_bib88","article-title":"Copper-doped polydopamine nanoparticles-mediated GSH\/GPX4-Depleted ferroptosis and cuproptosis sensitizes lung tumor to checkpoint blockade immunotherapy","volume":"21","author":"Jiang","year":"2025","journal-title":"Small Weinh. Bergstr. Ger."},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124551_bib89","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202417676","article-title":"Silk fibroin nanoparticles for enhanced cuproptosis and immunotherapy in pancreatic cancer treatment","volume":"12","author":"Gao","year":"2025","journal-title":"Adv. Sci."},{"issue":"21","key":"10.1016\/j.biomaterials.2026.124551_bib90","article-title":"One-step symbiosis of bimetallic peroxides nanoparticles to induce ferroptosis\/cuproptosis and activate cGAS-STING pathway for enhanced tumor immunotherapy","volume":"37","author":"Liu","year":"2025","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"issue":"26","key":"10.1016\/j.biomaterials.2026.124551_bib91","article-title":"Decoding GPX4 regulation in ferroptosis: mechanisms and therapeutic implications","volume":"S1471\u20134914","author":"Chen","year":"2026","journal-title":"Trends Mol. Med."},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124551_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.08.007","article-title":"Small-molecule GSDMD agonism in tumors stimulates antitumor immunity without toxicity","volume":"187","author":"Fontana","year":"2024","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biomaterials.2026.124551_bib93","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cell.2014.04.019","article-title":"RIPK1 regulates RIPK3-MLKL-Driven systemic inflammation and emergency hematopoiesis","volume":"157","author":"Rickard","year":"2014","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.03.020","article-title":"ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences","volume":"169","author":"Gong","year":"2017","journal-title":"Cell"},{"issue":"26","key":"10.1016\/j.biomaterials.2026.124551_bib95","article-title":"Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance","volume":"S0092\u20138674","author":"Lei","year":"2026","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.biomaterials.2026.124551_bib96","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1016\/j.cell.2026.06.001","article-title":"The cGAS-STING pathway: mechanism and medical implications","volume":"189","author":"Hooftman","year":"2026","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib97","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s43556-025-00330-2","article-title":"Single-cell multi-omics in biliary tract cancers: decoding heterogeneity, microenvironment, and treatment strategies","volume":"6","author":"Tang","year":"2025","journal-title":"Mol. Biomed."},{"issue":"18","key":"10.1016\/j.biomaterials.2026.124551_bib98","article-title":"Tumor-specific photothermal-therapy-assisted immunomodulation via multiresponsive adjuvant nanoparticles","volume":"35","author":"Liu","year":"2023","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"issue":"19","key":"10.1016\/j.biomaterials.2026.124551_bib99","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1039\/D3BM01265D","article-title":"Dual-responsive PEG-lipid polyester nanoparticles for siRNA and vaccine delivery elicit anti-cancer immune responses by modulating tumor microenvironment","volume":"11","author":"Liu","year":"2023","journal-title":"Biomater. Sci."},{"issue":"31","key":"10.1016\/j.biomaterials.2026.124551_bib100","article-title":"Extracellular vesicle-inspired minimalist flexible nanocapsules assembled with whole active ingredients for highly efficient enhancement of DC-Mediated tumor immunotherapy","volume":"13","author":"He","year":"2024","journal-title":"Adv. Healthcare Mater."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib101","first-page":"26","article-title":"Tumor organoids: breakthroughs in clinical decision making, drug development, and translational advances beyond conventional models","volume":"2","author":"Wu","year":"2026","journal-title":"Med Res"},{"key":"10.1016\/j.biomaterials.2026.124551_bib102","article-title":"Zinc oxide nanoparticles induce acute lung injury via oxidative stress-mediated mitochondrial damage and NLRP3 inflammasome activation: in vitro and in vivo studies","volume":"341","author":"Zhuo","year":"1987","journal-title":"Environ. Pollut. Barking Essex"},{"key":"10.1016\/j.biomaterials.2026.124551_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2023.11.021","article-title":"Mitochondria-targeted SkQ1 nanoparticles for dry eye disease: inhibiting NLRP3 inflammasome activation by preventing mitochondrial DNA oxidation","volume":"365","author":"Huang","year":"2024","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.biomaterials.2026.124551_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1407782","article-title":"Reactive oxygen species-responsive supramolecular deucravacitinib self-assembly polymer micelles alleviate psoriatic skin inflammation by reducing mitochondrial oxidative stress","volume":"15","author":"Yao","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2026.124551_bib105","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jfutfo.2024.10.009","article-title":"Efficacy and mechanisms of ci-gu-tang against pancreatic cancer: a study using patient-derived models","volume":"6","author":"Li","year":"2026","journal-title":"J. Future Foods"},{"key":"10.1016\/j.biomaterials.2026.124551_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2026.104150","article-title":"Rewiring immunometabolism in hepato-biliary-pancreatic cancers: unraveling TME-mediated metabolic suppression and advancing next-generation immunotherapeutic approaches","author":"Wu","year":"2026","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biomaterials.2026.124551_bib107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2020.07.001","article-title":"Manipulating the function of tumor-associated macrophages by siRNA-Loaded lipid nanoparticles for cancer immunotherapy","volume":"325","author":"Shobaki","year":"2020","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"599","key":"10.1016\/j.biomaterials.2026.124551_bib108","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2026.124551_bib109","article-title":"Food and medicine homology substances in cancer management","author":"Wu","year":"2026","journal-title":"Food Sci. Hum. Wellness"},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib110","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1021\/acsami.0c18545","article-title":"Hierarchically releasing bio-responsive nanoparticles for complete tumor microenvironment modulation via TGF-\u03b2 pathway inhibition and TAF reduction","volume":"13","author":"Zhang","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"14","key":"10.1016\/j.biomaterials.2026.124551_bib111","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211579","article-title":"Composite hydrogel for spatiotemporal lipid intervention of tumor milieu","volume":"35","author":"Ma","year":"2023","journal-title":"Adv. Mater."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib112","article-title":"Enhancing gastric cancer immunotherapy: insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms","volume":"7","author":"Qiu","year":"2026","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib113","article-title":"Targeting DNA damage and repair machinery via delivering WEE1 inhibitor and platinum (IV) prodrugs to stimulate STING pathway for maximizing chemo-immunotherapy in bladder cancer","volume":"36","author":"Wang","year":"2024","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124551_bib114","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1021\/acsnano.4c10202","article-title":"A pH-Responsive and guanidinium-rich nanoadjuvant efficiently delivers STING agonist for cancer immunotherapy","volume":"19","author":"Lu","year":"2025","journal-title":"ACS Nano"},{"issue":"26","key":"10.1016\/j.biomaterials.2026.124551_bib115","article-title":"Coordination and redox dual-responsive mesoporous organosilica nanoparticles amplify immunogenic cell death for cancer chemoimmunotherapy","volume":"17","author":"Zhang","year":"2021","journal-title":"Small Weinh. Bergstr. Ger."},{"key":"10.1016\/j.biomaterials.2026.124551_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111022","article-title":"Double security drug delivery system DDS constructed by multi-responsive (pH\/Redox\/US) microgel","volume":"193","author":"Lei","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.biomaterials.2026.124551_bib117","article-title":"Salvianolic acid B-Loaded polydopamine-modified hollow mesoporous organic silica nanoparticles for treatment of breast cancer metastasis via suppressing cancer-associated fibroblasts","volume":"192","author":"Hu","year":"2024","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"issue":"49","key":"10.1016\/j.biomaterials.2026.124551_bib118","article-title":"Dual-cascade responsive nanoparticles enhance pancreatic cancer therapy by eliminating tumor-resident intracellular bacteria","volume":"34","author":"Kang","year":"2022","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"issue":"50","key":"10.1016\/j.biomaterials.2026.124551_bib119","doi-asserted-by":"crossref","first-page":"34568","DOI":"10.1021\/jacs.4c12264","article-title":"Lysosome-mitochondria Cascade targeting nanoparticle drives robust pyroptosis for cancer immunotherapy","volume":"146","author":"Liu","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.biomaterials.2026.124551_bib120","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1021\/jacs.5c19678","article-title":"A spatially controllable DNA origami-based T-Cell cluster engager for precise tumor elimination","volume":"148","author":"Li","year":"2026","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biomaterials.2026.124551_bib121","doi-asserted-by":"crossref","DOI":"10.1177\/15353508241245265","article-title":"Combining nuclear medicine with other modalities: future prospect for multimodality imaging","volume":"23","author":"Archibald","year":"2024","journal-title":"Mol. Imaging"},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib122","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1186\/s12951-026-04205-8","article-title":"Ultrasound-assisted multimodal neuromodulation via nanosystems","volume":"24","author":"Nizami","year":"2026","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.biomaterials.2026.124551_bib123","article-title":"Epileptogenic zone-targeting nanoparticle drug delivery system for antiseizure medication","volume":"35","author":"Ping","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"25","key":"10.1016\/j.biomaterials.2026.124551_bib124","doi-asserted-by":"crossref","first-page":"22739","DOI":"10.1021\/acsnano.4c15868","article-title":"Self-driving and detachable lab-microrobots tailor drug delivery for closed-loop stimulation of the antitumor immune cycle","volume":"19","author":"Huang","year":"2025","journal-title":"ACS Nano"},{"issue":"19","key":"10.1016\/j.biomaterials.2026.124551_bib125","doi-asserted-by":"crossref","first-page":"8134","DOI":"10.1039\/D5MH00644A","article-title":"Focused ultrasound-responsive artificial killer cells for enhanced closed-loop cancer immunotherapy","volume":"12","author":"Zhang","year":"2025","journal-title":"Mater. Horiz."},{"issue":"46","key":"10.1016\/j.biomaterials.2026.124551_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202401398","article-title":"Closed-loop control of macrophage engineering enabled by focused-ultrasound responsive mechanoluminescence nanoplatform for precise cancer immunotherapy","volume":"20","author":"Xu","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2026.124551_bib127","doi-asserted-by":"crossref","DOI":"10.1177\/15353508241257924","article-title":"PET\/CT in the evaluation of CAR-T cell immunotherapy in hematological malignancies","volume":"23","author":"Singh","year":"2024","journal-title":"Mol. Imaging"},{"issue":"15","key":"10.1016\/j.biomaterials.2026.124551_bib128","article-title":"Electro-stimulated graphene-polymer nanocomposites enable wearable patches with feedback-controlled drug release","volume":"15","author":"Misra","year":"2026","journal-title":"Adv. Healthcare Mater."},{"issue":"4","key":"10.1016\/j.biomaterials.2026.124551_bib129","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1039\/D5CS01406A","article-title":"Artificial intelligence-powered nanomedicine","volume":"55","author":"Luo","year":"2026","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biomaterials.2026.124551_bib130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jconrel.2024.03.019","article-title":"A quantitative MRI-based approach to estimate the permeation and retention of nanomedicines in tumors","volume":"368","author":"Nomani","year":"2024","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"key":"10.1016\/j.biomaterials.2026.124551_bib131","doi-asserted-by":"crossref","DOI":"10.2147\/IJN.S618407","article-title":"Nanomedicine in 2026: illustrative quantitative analyses of EPR heterogeneity, clinical trial attrition, and emerging Horizons for active nanotherapeutics","volume":"21","author":"Fayez","year":"2026","journal-title":"Int. J. Nanomed."},{"issue":"26","key":"10.1016\/j.biomaterials.2026.124551_bib132","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202312169","article-title":"Nanomedicine tumor targeting","volume":"36","author":"Lammers","year":"2024","journal-title":"Adv. Mater."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124551_bib133","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s44222-024-00203-3","article-title":"Nanoparticle delivery to tumours: from EPR and ATR mechanisms to clinical impact","volume":"2","author":"Dasgupta","year":"2024","journal-title":"Nat. Rev. Bioeng."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124551_bib134","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.trecan.2017.06.006","article-title":"Cancer nanomedicine: lessons for immuno-oncology","volume":"3","author":"Sengupta","year":"2017","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib135","article-title":"Food and medicine homology in cancer treatment: traditional thoughts collide with scientific evidence","volume":"2","author":"Li","year":"2025","journal-title":"Food Med. Homol."},{"issue":"7","key":"10.1016\/j.biomaterials.2026.124551_bib136","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10427","key":"10.1016\/j.biomaterials.2026.124551_bib139","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.biomaterials.2026.124551_bib137","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"IMpassion130 trial investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biomaterials.2026.124551_bib140","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","article-title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial","volume":"20","author":"Bonvalot","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10409","key":"10.1016\/j.biomaterials.2026.124551_bib138","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124551_bib141","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/annonc\/mdx493","article-title":"A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma","volume":"28","author":"Voss","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"10","key":"10.1016\/j.biomaterials.2026.124551_bib142","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","article-title":"Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial","volume":"4","author":"Autio","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.biomaterials.2026.124551_bib144","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1158\/1078-0432.CCR-10-0978","article-title":"Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal Gold-rhTNF nanomedicine","volume":"16","author":"Libutti","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124551_bib145","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.biomaterials.2026.124551_bib146","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202504672","article-title":"Precision-guided stealth missiles in biomedicine: biological carrier-mediated nanomedicine hitchhiking strategy","volume":"12","author":"Zhou","year":"2025","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.biomaterials.2026.124551_bib147","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","article-title":"Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation","volume":"10","author":"Taha","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"issue":"9","key":"10.1016\/j.biomaterials.2026.124551_bib148","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.xphs.2023.07.002","article-title":"Role of particle size in translational research of nanomedicines for successful drug delivery: discrepancies and inadequacies","volume":"112","author":"Chan","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biomaterials.2026.124551_bib149","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jconrel.2023.11.043","article-title":"Impact of the physical-chemical properties of Poly(Lactic Acid)-Poly(Ethylene glycol) polymeric nanoparticles on biodistribution","volume":"365","author":"Jackman","year":"2024","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"1","key":"10.1016\/j.biomaterials.2026.124551_bib150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2011.03.007","article-title":"Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101","volume":"153","author":"Svenson","year":"2011","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"23","key":"10.1016\/j.biomaterials.2026.124551_bib151","doi-asserted-by":"crossref","first-page":"15284","DOI":"10.1021\/acsnano.4c04685","article-title":"Pharmaceutical quality by design approach to develop high-performance nanoparticles for magnetic hyperthermia","volume":"18","author":"Ansari","year":"2024","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.biomaterials.2026.124551_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.70663","article-title":"Liposome particle size prediction by In-Line process analytical technology (PAT)-integrated machine learning","volume":"10","author":"Lee","year":"2026","journal-title":"Small Methods"},{"issue":"20","key":"10.1016\/j.biomaterials.2026.124551_bib153","doi-asserted-by":"crossref","first-page":"28982","DOI":"10.1021\/acsami.5c02810","article-title":"Advances in ultrasmall inorganic nanoparticles for nanomedicine: from diagnosis to therapeutics","volume":"17","author":"Oh","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biomaterials.2026.124551_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2026.115925","article-title":"Anti-PEG antibodies in nanomedicine: mechanisms, risks, and opportunities","volume":"236","author":"Mihindukulasooriya","year":"2026","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biomaterials.2026.124551_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123854","article-title":"Short-chain dense brush PEGylation on rigid nanocarriers overcomes Anti-PEG antibody recognition for immune-stealth drug delivery","volume":"328","author":"Chen","year":"2026","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.biomaterials.2026.124551_bib156","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41563-024-02116-3","article-title":"High-density brush-shaped polymer lipids reduce Anti-PEG antibody binding for repeated administration of mRNA therapeutics","volume":"24","author":"Xiao","year":"2025","journal-title":"Nat. Mater."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226005752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961226005752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:57:03Z","timestamp":1790308623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961226005752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":156,"alternative-id":["S0142961226005752"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124551","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Logic-gated nanoregulators: A paradigm shift from drug delivery to pre-programmed multi-target immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2026.124551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124551"}}